Scholarlink

Background <p>Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&amp;E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and compared its performance to other risk models.</p> Methods <p>We retrospectively analyzed PDxBR in a cohort of 739 patients with early-stage hormone receptor-positive, HER2-negative breast cancer (median follow-up of 8.8 years). For each case, one H&amp;E-stained slide was digitized and analyzed to generate recurrence risk scores using the full PDxBR model, as well as image-only and clinical-only variants. A subset of patients who underwent MammaPrint testing was also evaluated. Model performance was assessed by AUC/C-index, hazard ratios, sensitivity, specificity, and negative and positive predictive values (NPV and PPV, respectively).</p> Results <p>PDxBR showed prognostic accuracy in this external cohort (AUC/C-index 0.71, 95% CI: 0.66–0.75). Applying the PDxBR threshold (≥ 58 versus &lt; 58) yielded a hazard ratio of 3.05 (95% CI: 2.1–4.4, <i>p</i> &lt; 0.001), sensitivity 0.70, specificity 0.59, NPV 0.90, and PPV 0.27. PDxBR outperformed the modified Adjuvant! Online clinical model (MINDACT model, <i>p</i> &lt; 0.00001) and effectively reclassified grade 2 tumors into distinct risk groups.</p> Conclusions <p>PDxBR demonstrated robust prognostic performance in an independent cohort, supporting its potential as a scalable, reproducible alternative to genomic assays for individualized risk stratification in early-stage breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月20日

查看全文
  • Pieter J. Westenend,
  • Claudia Meurs,
  • Gerardo Fernandez,
  • Marcel Prastawa,
  • Abishek Sainath Madduri,
  • Aaron Feliz,
  • Juan Carlos Mejias,
  • Alexander Shtabsky,
  • Xiaozhu Zhang,
  • Brandon Veremis,
  • Rebecca DeAngel,
  • Michael J. Donovan

摘要

Background

Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and compared its performance to other risk models.

Methods

We retrospectively analyzed PDxBR in a cohort of 739 patients with early-stage hormone receptor-positive, HER2-negative breast cancer (median follow-up of 8.8 years). For each case, one H&E-stained slide was digitized and analyzed to generate recurrence risk scores using the full PDxBR model, as well as image-only and clinical-only variants. A subset of patients who underwent MammaPrint testing was also evaluated. Model performance was assessed by AUC/C-index, hazard ratios, sensitivity, specificity, and negative and positive predictive values (NPV and PPV, respectively).

Results

PDxBR showed prognostic accuracy in this external cohort (AUC/C-index 0.71, 95% CI: 0.66–0.75). Applying the PDxBR threshold (≥ 58 versus < 58) yielded a hazard ratio of 3.05 (95% CI: 2.1–4.4, p < 0.001), sensitivity 0.70, specificity 0.59, NPV 0.90, and PPV 0.27. PDxBR outperformed the modified Adjuvant! Online clinical model (MINDACT model, p < 0.00001) and effectively reclassified grade 2 tumors into distinct risk groups.

Conclusions

PDxBR demonstrated robust prognostic performance in an independent cohort, supporting its potential as a scalable, reproducible alternative to genomic assays for individualized risk stratification in early-stage breast cancer.